Current and Emerging Treatments for IBD

This program will include a discussion of investigational agents not approved by the FDA for use in the United States.

IBD Background

Evolving Treatment Landscape in IBD

Limitations of Current IBD Therapies

Investigational Therapies: MOAs

Anti-Integrin Therapies

Selective Adhesion Molecule Inhibitors

Etrolizumab in Moderate to Severe UC Phase 2 Study

Etrolizumab in Moderate to Severe UC Phase 2 Study Results

Abrilumab in Moderate to Severe UC Phase 2b Study

Abrilumab in Moderate to Severe UC Phase 2b Study Results

PF-00547659 Anti-MAdCAM-1 Antibody TURANDOT Study

S1P Receptor Modulators

S1P Receptor Modulators (cont)

Ozanimod in Moderate to Severe UC TOUCHSTONE Study

TOUCHSTONE Efficacy Results

Emerging Anti-Interleukin mAbs in IBD

Ustekinumab for IBD

Risankizumab in Moderate to Severe CD Phase 2 Study

Risankizumab in Moderate to Severe CD Phase 2 Study Results

Brazikumab in Moderate to Severe CD Phase 2a Study

Mirikizumab in IBD

JAK Inhibitors

OCTAVE Trials: Tofacitinib in UC

OCTAVE 1 and 2 Efficacy Results

OCTAVE Sustain Efficacy Results

OCTAVE: Efficacy by Prior TNF Inhibitor Exposure

OCTAVE: Adverse Events

Filgotinib in Moderate to Severe CD FITZROY Study

Filgotinib in Moderate to Severe CD FITZROY Study Results

Upadacitinib in Moderate to Severe CD Celest Study

Upadacitinib in Moderate to Severe CD Celest Study Results

Other Emerging Therapies Rifaximin

Other Emerging Therapies in IBD

Possibilities for Future Treatment in IBD

Abbreviations

Abbreviations (cont)